Page 1

ASX Announcement 12 October 2026 ✓ Cogstate Cogstate Limited ABN 80 090 975 723 Level 32 367 Collins Street Melbourne , Vic , 3000 Australia P +61 3 9664 1300 F +61 3 9664 1301 W cogstate.com Cogstate 1Q27 Business Update All figures in US $ , unless stated Cogstate Ltd ( ASX : CGS ) , a global leader in clinical trial endpoint data quality and digital cognitive assessments , today releases a business update for the quarter ended 30 September 2026 ( " 1Q27 ” ) . Net sales contracts executed during 1Q27 totalled $ 25.1 million . The result reflects continued execution of the Company's strategy to combine scientific leadership in CNS endpoint quality with a growing channel partnership ecosystem , allowing sponsors to access Cogstate's expertise while working with their preferred clinical technology providers . A table of recent quarterly results for net sales contracts executed is provided below for context : Sep Quarter Dec Quarter Mar Quarter Jun Quarter Total Sales Contracts Executed FY27 US $ Million 25.13 FY26 FY25 US $ Million US $ Million 21.42 11.40 N / A 20.29 8.90 N / A 25.44 7.01 N / A 21.85 13.95 25.13 89.00 41.26 The September quarter sales results demonstrated Cogstate's ability to win market share in mood disorders , including the competitive win of five Phase 3 trials in either bipolar or depression , across two customers , contributing over 80 % of the total contract sales value executed during the quarter . Sponsors commonly retain providers from earlier phases of development when progressing to Phase 3 studies . The Company's channel partnership strategy was an important factor in its appointment to these programs . By enabling sponsors to work with their preferred data capture and clinical technology providers , while leveraging Cogstate's expertise in endpoint quality and complex global study execution , Cogstate was able to secure work that may historically have been more difficult to win independently . Contracted Revenue The table below provides analysis of Cogstate's contracted revenue position at 30 September 2026 : Contracted Revenue PCP Growth ( incl . revenue recognised in 1Q27 ) US $ Million ( incl . revenue recognised in 1Q26 ) US $ Million % 1H27 $ 31.7 $ 23.0 38 % FY27 ( incl . 1H27 ) $ 56.8 $ 39.2 45 % FY28 - FY33 $ 86.9 $ 62.6 39 % Overall Total $ 143.7 $ 101.8 41 % * PCP = Previous Corresponding Period | Page 1